HemaQuest Wins Orphan Drug Designations for Anemia Drug
Posted on: Wednesday, 5 November 2008, 12:00 CST
HemaQuest Pharmaceuticals, a biopharmaceutical company, has announced that the FDA has awarded the company orphan drug designations for sickle cell anemia and beta thalassemia for HQK-1001, which is an orally administered therapeutic under clinical development for these two indications.
HemaQuest has recently completed Phase I clinical trials of HQK-1001 in healthy subjects and plans to begin clinical studies of this compound in both sickle cell anemia and beta thalassemia in the near future.
The compound's therapeutic potential was discovered by Susan Perrine, the company's chief scientific officer and vice president of clinical affairs, and her colleagues at Boston University.
Ronald Berenson, president and CEO of HemaQuest, said: "Orphan drug designations confirm the urgent medical need to develop new therapies to treat these two serious and life-threatening hemoglobin disorders. These designations by the FDA also provide us with strong incentives for our novel proprietary drug candidate, HQK-1001, which initially is being developed to treat both sickle cell anemia and beta thalassemia."
Source: Datamonitor
Related Articles
- Blood Stem-Cell Transplant Regimen Reverses Sickle Cell Disease in Adults
- Cell Therapeutics Applies for European Orphan Drug Designation for Pixantrone in Aggressive Non-Hodgkin's Lymphoma (NHL)
- BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
- Stem Cells Used to Cure Sickle-Cell Anemia in Mice
- BioMarin Initiates Phase 2a Clinical Study of 6R-BH4 in Sickle Cell Disease
- Alba Announces Completion of Enrollment and Dosing of Patients in Phase II Clinical Trial of AT-1001 for the Treatment of Celiac Disease
- Icagen Initiates Pediatric Clinical Development of ICA-17043 for Sickle Cell Disease
- Stem Cells Used to Correct Sickle Cell
- Alba Therapeutics Announces Completion of First Human Trial for AT-1001 and FDA ''Fast Track'' Designation
 |
 |
User Comments (0)
RSS Feeds